REVEAL is an open-label phase 1b/2 study of omaveloxolone (RTA 408) in combination with either ipilimumab or nivolumab for the treatment of melanoma.

**Criteria for Participation**

18 years of age or older

Diagnosis of unresectable (stage 3) or metastatic (stage 4) melanoma

Previous treatment with ipilimumab, nivolumab, or both is allowed

**Treatment**

Omaveloxolone (RTA 408) capsules taken by mouth once daily in combination with ipilimumab or nivolumab

Cost of travel to the study site may be reimbursed

**Study Duration**

Approx 24 Weeks (ipilimumab)

Approx 48 weeks (nivolumab)

**Recruiting Study Center Locations**

United States

- Mobile, Alabama: Southern Cancer Center
  Michael Meshad, MD
- Fayetteville, Arkansas: Highlands Oncology Group
  Thaddeus J Beck, MD
- Aurora, Colorado: University of Colorado
  Rene Gonzalez, MD
- Newark, Delaware: Christiana Hospital
  Michael Guarino, MD
- Tampa, Florida: H. Lee Moffitt Cancer Center
  Joseph Markowitz, MD
- Boston, Massachusetts: Dana Farber Cancer Institute
  Frank Hodi, MD
- Morristown, New Jersey: Atlantic Melanoma Center
  Eric Whitman, MD
- Durham, North Carolina: Duke Cancer Institute
  April Salama, MD
- Houston, Texas: MD Anderson Cancer Center
  Sapna Patel, MD

Contact information for participating study centers can be found on the clinicaltrials.gov listing.